Weekly ReportDec 1–7, 2025
Sepsis, week 49 edition
We read 21 papers and selected 3.
Summary
This week’s sepsis research reinforced that the syndrome is biologically dynamic and highly heterogeneous: immune endotypes shift over hours, while infection source, age, cancer status, and organ-specific biology shape risk. Multi-omic studies converged on mitochondrial dysfunction, immunometabolic reprogramming, programmed cell death, and tissue-specific immune programs as major drivers of poor outcomes. Translational advances included novel targets such as ERRγ, GYG1, mitophagy pathways, and the platelet–mast cell axis, alongside improved diagnostic approaches including mNGS, dried-blood multi-omics, AI prediction, and hemodynamic phenotyping beyond MAP. Clinically, anticoagulation may provide a modest survival benefit but increases bleeding, emphasizing the need for biomarker-guided and risk-adapted treatment.
Selected Articles
1. Single-cell multi-omic landscape reveals anatomical-specific immune features in adult and pediatric sepsis.
In 281 adults and children with sepsis and controls, integrated single-cell transcriptomics, T-cell and B-cell receptor sequencing, CITE-seq, bulk RNA sequencing, and plasma proteomics showed that the anatomical source of infection imprints distinct immune programs. The study identified shared core features across ages as well as source- and age-specific states, including an NR4A2-associated signature, providing a reference map for precision sepsis stratification.
Impact: This large, deeply phenotyped human study reframes sepsis heterogeneity around anatomical infection source and age rather than treating sepsis as a uniform systemic syndrome. Its integrated molecular reference map can directly inform biomarker development, trial enrichment, and source-specific immunomodulation.
Clinical Implications: Future sepsis diagnostics and trials should account for infection source and patient age when interpreting immune biomarkers. Source-specific immune signatures may improve prognosis, identify patients for targeted immunomodulation, and reduce heterogeneity in clinical trials, but prospective clinical utility studies are still required.
Key Findings
- Integrated multi-omics in 281 individuals identified infection-site-specific immune programs across adult and pediatric sepsis.
- Adult and pediatric sepsis shared core immune features but also showed distinct source- and age-related states.
- An NR4A2-associated signature emerged as a candidate marker of sepsis immune heterogeneity.
2. Longitudinal multi-omic signatures of ARDS and sepsis inflammatory phenotypes identify pathways associated with mortality.
Longitudinal metabolomic and transcriptomic profiling of 160 ARDS patients identified four mortality-associated molecular signatures linked to innate immune activation, glycolysis, hepatic and immune dysfunction, impaired fatty acid oxidation, interferon suppression, redox impairment, and mitochondrial dysfunction. The signatures persisted through day 2 and were validated in an independent critically ill sepsis cohort, supporting a mechanistic framework for endotype-guided therapy.
Impact: This study provides validated biological depth beneath conventional inflammatory phenotypes and identifies mitochondrial dysfunction as a common mechanistic denominator. It shifts precision sepsis research from descriptive immune classes toward longitudinal, pathway-based treatment selection.
Clinical Implications: Mitochondrial bioenergetics, fatty acid oxidation, interferon signaling, and redox pathways are plausible targets for endotype-enriched trials. Repeated molecular profiling may help determine which pathway is active and when intervention is most likely to be beneficial, although causal and therapeutic validation is pending.
Key Findings
- Four mortality-associated molecular signatures were identified across inflammatory phenotypes.
- All signatures converged on or included mitochondrial dysfunction-related biology and persisted from day 0 to day 2.
- The molecular signatures were externally validated in an independent critically ill sepsis cohort.
3. Efficacy and safety of anticoagulant therapy in patients with sepsis: a meta-analysis of randomized controlled trials.
A meta-analysis of 18 randomized controlled trials involving 8,053 patients found that anticoagulant therapy reduced 28- or 30-day all-cause mortality by 8% relative to placebo or no treatment, but increased bleeding risk by 32%. In patients with baseline disseminated intravascular coagulation, anticoagulants improved DIC regression without a statistically significant mortality benefit, clarifying the need for careful patient selection.
Impact: As the week’s highest-level therapeutic evidence, this study directly informs a clinically active controversy and quantifies the trade-off between modest survival benefit and bleeding harm. It supports neither universal anticoagulation nor complete avoidance, but rather a risk-adapted strategy.
Clinical Implications: Anticoagulation may be considered in selected patients with sepsis after assessing bleeding risk, coagulation phenotype, organ dysfunction, and treatment indication. In sepsis-associated DIC, clinicians should recognize that laboratory or syndrome improvement may not translate into lower mortality, and individualized monitoring is essential.
Key Findings
- Across 18 randomized trials and 8,053 patients, anticoagulants reduced all-cause mortality with a relative risk of 0.92.
- Bleeding complications increased with anticoagulation, with a relative risk of 1.32.
- In baseline DIC, anticoagulation improved DIC regression but did not significantly reduce mortality.